EHA 2023 | Phase I/II study of a novel BET inhibitor, BMS-986158, alone & with ruxolitinib or fedratinib in MF
Haifa Kathrin Al-Ali, MD, Martin Luther University of Halle-Wittenberg, Halle, Germany, shares the results of CA011-023 (NCT04817007), a Phase I/II study evaluating BMS-986158, a BET inhibitor, as monotherapy or in combination with ruxolitinib in the first-line treatment of patients with myelofibrosis (MF), or with fedratinib in the second-line setting in patients intolerant to ruxolitinib. The study reported that these combinations were well tolerated, with thrombocytopenia and gastrointestinal (GI) toxicity as the main side effects. Preliminary efficacy data indicate significant spleen volume reduction, reduction in bone marrow fibrosis and in the JAK2 mutant allele burden. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support from Novartis, Bristol Myers Squibb and Incyte, participating on a scientific advisory board for Novartis, Bristol Myers Squibb, Abbvie, SGK, Blue Print, AOP Pharma, travel grant from Bristol Myers Squibb and Abbvie
